Drug intelligence / Profile preview

cyclosporine + methylprednisolone + prednisolone

Development stage: Unknown
Lead developer: Pfizer
Modality: Small Molecules
Administration: Oral, Intravenous

Overview

A combination immunosuppressive regimen consisting of cyclosporine (a calcineurin inhibitor) with methylprednisolone and prednisolone (both corticosteroids). This triple therapy is used primarily in organ transplantation to prevent rejection and in severe autoimmune disorders. The combination provides synergistic immunosuppression through complementary mechanisms - cyclosporine inhibits T-cell activation and proliferation by blocking calcineurin, while the corticosteroids provide broader anti-inflammatory effects through multiple pathways.

Targets

GR (Glucocorticoid receptor)CN (Calcineurin)

Beyond the preview

Go deeper on cyclosporine + methylprednisolone + prednisolone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on cyclosporine + methylprednisolone + prednisolone.

Explore the full profile